(Houston, December 14, 2018). RadioMedix Inc has been selected by the National Cancer Institute (NCI) Small Business Innovation Research Development Center (SBIR) to participate in 2018 BIO Investor Forum. The company received federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services (HHSN261201600015C, HHS261201800048C/75N91018C00048) for the development of radiotherapeutic alpha-emitter labeled agents.
Dr. Izabela Tworowska, Chief Science Officer of RadioMedix, presented an overview of the company pipeline, the financial growth of RadioMedix, and status of the clinical development of radiotheranostic drugs. The presentation was sponsored by NCI SBIR Development Center’s Investor Initiatives program.
“We have been invited to attend the BIO Investor Forum in San Francisco for two consecutive years and we are grateful to the NCI SBIR Investor Initiatives for this invitation “, said Dr. Tworowska. “It is a great opportunity to attend BIO One-on-One Partnering meetings, discuss the future goals of our company and gain the interest of investors and business partners”, added Dr. Tworowska.
“RadioMedix’s rich clinical stage pipeline of innovative radiopharmaceuticals makes an attractive case for investors, and large companies, familiar with our space”, said Dr. Delpassand, Chairman and CEO of RadioMedix. “Targeted radioligand therapy will be the strongest segment in the field of nuclear medicine and RadioMedix is well-positioned to take advantage of this opportunity”, added Dr. Delpassand.
RadioMedix, Inc. is a clinical stage biotechnology company, based in Houston, Texas, focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring and, therapy of cancer. The company is commercializing radiopharmaceuticals for PET imaging and therapeutic (alpha and beta-labeled) radiopharmaceuticals for targeted radionuclide therapy in cancer. RadioMedix has also established two service facilities for academic and industrial partners: cGMP Manufacturing Suite for human clinical trials and probe development and small animal Molecular Imaging Facility for pre-clinical evaluation of radiopharmaceuticals in animal models. RadioMedix completed the Phase II clinical studies of the kidney protection agents, AminoMedixTM. The clinical Phase I studies of AlphaMedixTM , the alpha emitter labeled drug targeting of neuroendocrine patients are on-going. For more information, please visit the Company’s websites at www.radiomedix.com , and follow us on Facebook and LinkedIn.
About BIO and the BIO Investor Forum
BIO, the Biotechnology Innovation Organization, is the world’s largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and, related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.
The BIO Investor Forum is an international biotechnology investor conference focused on early and established private companies as well as emerging public companies. The event features plenary sessions, business roundtables and therapeutic workshops, company presentations, and One-on-one Partnering™ meetings.